emb-01
mAbexperimentalMulti-specific
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Dec 13, 2018 (NCT03797391)
Timeline
Indications
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
- Hepatocyte growth factor receptorINHIBITOR
Hepatocyte growth factor receptor inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594472 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05498389 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2022 | LabCorp, Shanghai EpimAb Biotherapeutics Co., Ltd. |
| NCT05176665 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2021 | LabCorp, Shanghai EpimAb Biotherapeutics Co., Ltd. |
| NCT04868253 | Phase 2/Phase 3 (Phase 3) | May 19, 2021 | Embera NeuroTherapeutics, Inc., Foundation for a Smoke-Free World, Rose Research Center, LLC |
| NCT03797391 | Phase 1/Phase 2 (Phase 2) | Dec 13, 2018 | Covance, Gabrail Cancer Center, Shanghai EpimAb Biotherapeutics Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai EpimAb Biotherapeutics Co., Ltd. | For profit | 3 | 3 | 1 | 2018 |
| LabCorp | For profit | 2 | 0 | 1 | 2021 |
| Covance | For profit | 1 | 0 | 1 | 2018 |
| Embera NeuroTherapeutics, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Foundation for a Smoke-Free World | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Rose Research Center, LLC | For profit | 1 | 1 | 1 | 2021 |
7 organizations
Page 1 / 1